Nei den kom nå @theroger
7,2 mg dosen har vært godkjent en stund. Satt med tre x 2.4 mg penner (og tilsvarende grusom pris). 2.4mg penna har obv vært godkjent en stund.
Nå er endelig 7,2 mg penna godkjent. Så nå kan man stikke seg en enkelt gang i uka å få 7,2 mg rett i bilringene
Edit: Men det er bra for Novo. Da har man endelig en ukentlig injeksjon som gir 20% nedgang i snitt-ish på markedet, med et kjent og kjært legemiddel. Settes prisen lavt nok er det muligheter for at 7,2mg sema kaprer deler av markedet til tirzepatide.
4 Likes
Ahaaa, okei takk 
1 Like
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
2026-05-26 10:41:00
- The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries - showed that cardiovascular (CV) inflammation remains highly prevalent among people with cardiovascular disease (CVD), despite current standard of care treatment1,2
- In fact, two in five people with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), or heart failure, have CV inflammation1,2
- This matters because CV inflammation is an independent risk factor for CV events, such as heart attack and stroke, in people living with CVD, and it shows a significant gap in CV care globally3
Bagsværd, Denmark, 26 May 2026 – Novo Nordisk today presented new results from the landmark POSEIDON real-world evidence study at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece. The study showed that CV inflammation remains highly prevalent among people with CVD despite current standard-of-care treatment. The study found that 2 in 5 people with ASCVD and CKD had CV inflammation, which is associated with an increased risk of major CV events2,4.
A second POSEIDON analysis recently published in the European Journal of Heart Failure showed that two in five people with heart failure also have CV inflammation1. In POSEIDON, CV inflammation was measured and defined by high-sensitivity C-reactive protein (hsCRP) levels ≥2 mg/L1. hsCRP is the most commonly used and widely available blood test for measuring CV inflammation4-6.
These findings underscore a significant gap in current CV care. Even when people receive guideline-recommended treatments to control, e.g., cholesterol, blood pressure and blood sugar, inflammation-driven CV risk persists3,7. The POSEIDON study represents one of the largest contemporary global assessments of CV inflammation prevalence in this high-risk population1,2.
“The POSEIDON study provides critical evidence that cardiovascular inflammation represents a significant source of persistent risk in people living with atherosclerotic cardiovascular disease and chronic kidney disease or heart failure, despite receiving standard of care treatment today,” said Filip Knop, senior vice president and chief medical officer at Novo Nordisk. “Understanding the scope of cardiovascular inflammatory risk is essential, as we continue our innovation-driven research to develop a first-in-class therapy with the potential to address this critical unmet need.”
POSEIDON enrolled 18,904 patients across 18 countries spanning Europe, North America, South America and Asia-Pacific between 2023 and 20251,2. Within the study, 13,475 patients had ASCVD, of whom 5,757 (42.7%) had CKD, while 11,809 patients had heart failure spanning across all types of heart failure (preserved, mildly reduced or reduced)1,2.
Cardiovascular inflammation plays a central role in the development and progression of ASCVD8,9. Multiple studies have shown that people with CV inflammation face an increased risk of major adverse cardiovascular events, including heart attack, stroke and CV death3-5. Inflammation also contributes to CKD progression, and CKD itself may promote inflammation, creating a cycle that amplifies CV risk9.
It also plays a key role in heart failure, and it is common across all types of heart failure, particularly in people with obesity, kidney disease and other metabolic conditions1,10.
“POSEIDON makes clear that inflammation is not a peripheral concern – it is a shared driver of risk affecting millions of patients worldwide with cardiovascular disease who remain vulnerable despite our best current therapies,” said Professor Carolyn S.P. Lam, Senior Consultant, Department of Cardiology, National Heart Centre Singapore; and Professor, Cardiovascular & Metabolic Disorders Signature Research Programme, Duke-NUS Medical School. “What is striking is the consistency of inflammatory signals across such diverse patient populations. That consistency points to a practical way forward – identifying patients most likely to benefit from therapies that directly target inflammation. This reframes how we should think about residual cardiovascular risk, and it underscores the promise of emerging anti-inflammatory therapies to address a real unmet need.”
The growing recognition of the role of inflammation in cardiovascular disease is reflected in recent guidelines from the European Society of Cardiology (ESC), the American Heart Association (AHA), and the American College of Cardiology (ACC), which include elevated hsCRP as a risk-modifying biomarker to guide more intensive preventive initiatives11,12.
1 Like
$NVO $NOVO Baptista Research upgrades Novo Nordisk to Buy from Hold and cuts the target price slightly to USD59.40 (c. DKK381) from USD59.50.
The new research report is entitled “Novo Nordisk’s 2 Million Prescription Surge — Is Wegovy Rewriting Obesity Care?”.
Baptista writes:
Novo Nordisk reported its first quarter 2026 financials and operational updates reflecting a complex interplay of market dynamics, product launches, and ongoing investments.
Adjusted sales declined by 4% on a constant exchange rate basis, primarily due to lower realized prices. This was partially offset by volume growth in GLP-1 therapies and expansion in obesity care, with international operations growing 6% while U.S. sales fell 11%.
Obesity care sales increased 22% overall, supported by both regions, with the international segment growing 44% driven by volume and market expansion despite pricing pressures in China following competitor price reductions.
The company emphasized the robust uptake of the recently launched Wegovy oral pill in the U.S., highlighting 1 million patients treated within 16 weeks and over 2 million total prescriptions since launch.
Early data indicate approximately 80% of users were treatment-naive to GLP-1, with limited cannibalization from injectable products.
3 Likes
Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions
- Phase 3 REIMAGINE 1–3 trial results across a range of type 2 diabetes patient groups offer further insight into CagriSema, a novel amylin RA and a GLP-1 RA in a fixed-dose combination1
- Mid-stage trial data for investigational zenagamtide explore the safety and efficacy of the injectable formulation of the novel GLP-1/amylin-based treatment2
- New Ozempic® and Wegovy® data provide further evidence of semaglutide’s strong cardiometabolic profile
PLAINSBORO, NJ and BAGSVÆRD, Denmark, May 27, 2026 /PRNewswire/ – Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association® (ADA), taking place in New Orleans, June 5–8, 2026. Phase 3 REIMAGINE 1–3 results evaluating the effects of investigational CagriSema on glycemic control and weight loss across a range of type 2 diabetes background therapies will be featured in a symposium.1 A total of 40 abstracts will be presented, including phase 2 data assessing the safety and efficacy of investigational once-weekly injectable zenagamtide, as well as new data for Ozempic® and Wegovy® building on the growing body of clinical evidence for semaglutide across multiple cardiometabolic conditions.2
“The ADA’s 2026 Scientific Sessions underscores the breadth and strength of our approach to cardiometabolic diseases. From amylin-based pipeline candidates to continued expansion of our portfolio, we are building on the established and unique profile of semaglutide,” said Martin Lange, executive vice president of Research & Development and chief scientific officer at Novo Nordisk. “As pioneers in this space, we remain focused on advancing innovation that can meaningfully improve the lives of millions living with serious chronic diseases.”
On Sunday, June 7, 2026, Novo Nordisk will host an R&D investor event on the science and abstracts presented at the conference. The event will be accessible via a live webcast on the Novo Nordisk investor website.
Select Novo Nordisk abstracts to be presented at The ADA’s 2026 Scientific Sessions, June 5 – 8, New Orleans: Data for investigational uses of semaglutide and investigational medicines containing CagriSema, zenagamtide, IcoSema, and efruxifermin.
Symposium:
- REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema – Sunday, June 7; 4:30–6:00 pm CDT
Novo Nordisk poster and oral presentations:
CagriSema
- 1035-OR Effects of CagriSema on Appetite and Functional Brain Activity in People with Overweight/Obesity – Friday, June 5; 12:45–1:45 pm CDT
- 1695-P Effect of CagriSema on Eating Control and Behavior: REDEFINE 1 – Sunday, June 7; 12:30–1:30 pm CDT
Zenagamtide
- 1730-P Zenagamtide (Amycretin), a Novel Unimolecular GLP-1 and Amylin Receptor Agonist: Phase 2b Results in T2D – Sunday, June 7; 12:30–1:30 pm CDT
- 1323-OR Zenagamtide Targets Key Feeding-Related Brain Regions and Induces Weight Loss by Preferentially Reducing Consumption of Unhealthy Solid and Liquid Diets in Rats – Monday, June 8; 2:30–2:45 pm CDT
Wegovy ® (semaglutide injection and tablets)
- 1669-P Effect of Semaglutide for Weight Management on Blood Pressure in Adults with Uncontrolled Hypertension and Overweight/Obesity: A Post Hoc Analysis from the STEP and OASIS Programs – Sunday, June 7; 12:30–1:30 pm CDT
- 2838-LB Cardiometabolic Effects of Semaglutide in OASIS 4 Participants by BMI Class – Sunday, June 7; 12:30–1:30 pm CDT
- 1685-P Exploring Semaglutide’s Effect on the ASCVD-Related Proteomic Signature and Their Prediction of MACE in SELECT – Sunday, June 7; 12:30–1:30 pm CDT
- 1703-P Semaglutide Reduces Multi-Organ Proteomic-Based Biological Age Across Cohorts – Sunday, June 7; 12:30–1:30 pm CDT
- 1723-P Semaglutide Reduces Asthma-Related Adverse Outcomes in Patients with Comorbid Asthma and Obesity: A Post Hoc Analysis of the SELECT Trial – Sunday, June 7; 12:30–1:30 pm CDT
- 1711-P Menopausal Hormonal Status and Estradiol Use Modulate Semaglutide-Associated Weight Loss in Women: Analyses from STEP 1 and SELECT – Sunday, June 7; 12:30–1:30 pm CDT
- 1728-P Large-Scale Proteomic Discovery of Prognostic and Treatment-Responsive CKD Biomarkers in SELECT – Sunday, June 7; 12:30–1:30 pm CDT
- 2840-LB Semaglutide 2.4 mg and Obstructive Sleep Apnea in Patients with Overweight or Obesity and Cardiovascular Disease: A Post Hoc Analysis of SELECT – Sunday, June 7; 12:30–1:30 pm CDT
- 2846-LB Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial – Sunday, June 7; 12:30–1:30 pm CDT
- 2829-LB STEP UP T2D: Participants Achieving BMI, WHtR, and Cardiometabolic Treatment Targets – Sunday, June 7; 12:30–1:30 pm CDT
- 2700-LB High-Dose Semaglutide Is Associated with Preservation of Kidney Function in People Living with Obesity Without Diabetes – Sunday, June 7; 12:30–1:30 pm CDT
- 1291-OR Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial – Monday, June 8; 2–2:15 pm CDT
Ozempic ® (semaglutide injection and tablets)
- 1775-P Effect of Subcutaneous Semaglutide on Cardiorenal Outcomes Across Type 2 Diabetes Subtypes: SUSTAIN 6 Post Hoc Analysis – Sunday, June 7; 12:30–1:30 pm CDT
- 1708-P Comparing Major Adverse Kidney Events (MAKE) among New Users of Oral Semaglutide (SEMA) Versus Select Oral Antidiabetic Medications (ADMs) Among US Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) – Sunday, June 7; 12:30–1:30 pm CDT
- 2835-LB Greater Combined A1C Reductions and Weight Loss with 25 mg and 50 mg vs 14 mg Oral Semaglutide in Adults with T2D: Evidence from PIONEER PLUS – Sunday, June 7; 12:30–1:30 pm CDT
- 2843-LB HbA1c and Weight Outcomes for Individuals with T2D Persistent on 25mg Oral Semaglutide: A PIONEER PLUS Post-Hoc Analysis – Sunday, June 7; 12:30–1:30 pm CDT
Semaglutide for MASH
- 1701-P Longitudinal Dynamics of Cardiometabolic Parameters in a MASH Population Stratified by Baseline Glycemia and Treated with Semaglutide: Post Hoc Insights from the ESSENCE Trial Part 1 – Sunday, June 7; 12:30–1:30 pm CDT
- 2592-P Impact of Once-Weekly Injectable Semaglutide Versus Placebo on Fatty Liver Index Scores in People with Overweight/Obesity: A Post Hoc Analysis (STEP 1) – Monday, June 8; 12:30–1:30 pm CDT
Insulin Icodec
- 1750-P Glucodynamics and Hypoglycemia Risk During Exercise or Fasting in Individuals with T2D Receiving Once-Weekly Basal Insulin Icodec – Saturday, June 6; 12:30–1:30 pm CDT
IcoSema
- 1752-P Improved Treatment Satisfaction with Once-Weekly IcoSema vs Once-Daily Glargine U100 in Insulin-Naive Adults with T2D (COMBINE 4) – Saturday, June 6; 12:30–1:30 pm CDT
- 1753-P CGM-Based Metrics in Insulin-Naive Adults with T2D Receiving IcoSema vs Glargine U100: Post Hoc Analysis of COMBINE 4 – Saturday, June 6; 12:30–1:30 pm CDT
- 1758-P Efficacy and Hypoglycemia Outcomes with Once-Weekly IcoSema vs Comparators in T2D by Baseline BMI: COMBINE 1-3 – Saturday, June 6; 12:30–1:30 pm CDT
- 1738-P Efficacy and Hypoglycemia Outcomes with Once-Weekly IcoSema vs Comparators in T2D by Baseline A1C: COMBINE 1-3 – Saturday, June 6; 12:30–1:30 pm CDT
Efruxifermin
- 1294-OR Efruxifermin Improved Liver Disease and Insulin Sensitivity in Participants with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis in the SYMMETRY Trial – Monday, June 8; 2:45–3:00 pm CDT
Cross-product
- 1696-P Effect of Semaglutide on COVID-19-Related Complications and All-Cause Death: Pooled Analyses of the SELECT, FLOW, and SOUL Trials – Sunday, June 7; 12:30–1:30 pm CDT
Non-product
- 2350-P Unmet Need in Post-Stroke Antidiabetic Treatment Patterns Among Individuals Newly Diagnosed with Type 2 Diabetes (T2D) During Ischemic Stroke Hospitalization – Saturday, June 6; 12:30–1:30 pm CDT
- 2834-LB Cardiometabolic Outcomes in Adults with T2D Treated with 1 mg Semaglutide Who Titrate to 2 mg Semaglutide vs. Switch to Tirzepatide - Sunday, June 7; 12:30–1:30 pm CDT
- 2717-LB Clinical and Economic Burden Associated with Painful Diabetic Peripheral Neuropathy (PDPN) in Patients with Type 2 Diabetes (T2D) - Sunday, June 7; 12:30–1:30 pm CDT
9 additional abstracts being presented at ADA will cover data related to cardiometabolic diseases including type 2 diabetes, obesity, kidney, and liver disease.
CagriSema, zenagamtide, IcoSema, and efruxifermin are not approved in the United States. Safety and efficacy are not established, and there is no guarantee that these investigational medicines will become commercially available for the uses under clinical investigation.
Pluss denne:
2 Likes
CVS tilbake med å dekke Zepbound
https://www.washingtonpost.com/health/2026/05/28/ozempic-may-be-reshaping-brain-scientists-say/
Mer kreft data:
OS at 24 months was higher among GLP1 users versus nonusers for both breast cancer (97.9% [95% CI 93.7–99.3] vs 92.6% [92.4–92.8]) and prostate cancer (97.9% [93.7–99.3] vs 92.6% [92.4–92.8]). After adjustment for age, BMI, stage, and cancer type, GLP1 use was significantly associated with improved OS (HR 0.58, 95% CI 0.40–0.84; p = 0.0036).
Har ikke GLP1 blitt testet på kreft før? I ordentlig fase 2/3 studie.
Overrasker meg ikke om det har stor effekt, når man vet hvor enorme positive effekter det har på kroppen og gå ned i vekt
1 Like
Nei, har vel bare blitt testet som tillegsinfo at det ikke øker kreftfaren etter hva jeg kan se. Er vel det litt av disse resultatene nå etterspør, at det trengs direkte større randomiserte studier som kan bekrefte signalene som er gitt her
“…supporting the need for future studies using robust causal inference approaches.”
“These findings warrant validation in prospective randomized controlled trials and mechanistic investigation of potential antineoplastic pathways driven by GLP-1RAs.”
1 Like
Begynner å komme litt data i dag:
1730-P Zenagamtide (Amycretin), a Novel Unimolecular GLP-1 and Amylin Receptor Agonist: Phase 2b Results in T2D:
1323-OR Zenagamtide Targets Key Feeding-Related Brain Regions and Induces Weight Loss by Preferentially Reducing Consumption of Unhealthy Solid and Liquid Diets in Rats
1035-OR Effects of CagriSema on Appetite and Functional Brain Activity in People with Overweight/Obesity
1695-P Effect of CagriSema on Eating Control and Behavior: REDEFINE 1
Resten kan sjekkes ut på ADA 2026 Scientific Sessions Planner
All data fra presentasjoner iløpet av neste uke
3 Likes
1 Like
Lurer på om ikke Altimmune sin lille fase II med 100 pasienter i AUD (Alcohol Use Disorder) burde lese av i løpet av sommeren. Blir spennede å se om man kan se effekt der.
1 Like
Noen som kjenner til årsaken bak dagens fall i Novo?
Markedet frykter NovoNordisk må betale for dyrt for en avtale med Nanexa 
Er generelt hele sektoren som faller litt tilbake. Lilly -6%, Viking -11%, Structure -11%, Gubra -6% og Zealand -8% de siste dagene.
EDIT:
Mange av disse vil nok forhåpentlig hente seg inn når fokuset flyttes mot ADA til helgen
3 Likes
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
2026-06-03 08:00:52
- Novo Nordisk launches Wegovy® pill in the United Arab Emirates today
- Wegovy® pill is indicated to reduce excess body weight and maintain weight reduction long-term
- Wegovy® pill, providing a mean weight loss of 17%, is the only weight-loss pill approved to reduce the risk of major adverse cardiovascular events (MACE), including heart attack and stroke, in adults with established cardiovascular disease and obesity or overweight
Bagsværd, Denmark, 3 June 2026 - Novo Nordisk today announced the launch of Wegovy® pill (semaglutide tablets) in the United Arab Emirates (UAE), the first country outside the United States to make the Wegovy® pill available to people living with obesity. The launch marks an important step in Novo Nordisk’s ambition to expand access to innovative obesity treatments and broaden treatment options for people living with obesity around the world.
“I am thrilled that Wegovy® pill is now available in the UAE,” said Emil Kongshøj Larsen, executive vice president, International Operations at Novo Nordisk. “This launch represents an important milestone in our ambition to expand access to innovative obesity care globally. As we look to future launches, our approach will be guided by local patient demand, the readiness of healthcare professionals, and the strength of healthcare and telehealth infrastructure that can support long-term obesity care. The UAE has demonstrated strong momentum across all of these areas, and we look forward to bringing Wegovy® pill to additional select countries in the coming months.”
The Wegovy® pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. The approval is based on the OASIS 4 trial programme.
In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated ~17% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities. The weight loss achieved with the Wegovy® pill is similar to that of injectable Wegovy® 2.4 mg. Furthermore, 1 in 3 people experienced 20% or greater weight loss in the OASIS 4 trial. The established safety and tolerability profile of semaglutide was reaffirmed with Wegovy® pill in the OASIS 4 trial, which was comparable to previous trials with semaglutide for weight management.
Wegovy® pill is also the only weight-loss pill approved by both the FDA and the Emirates Drug Establishment (EDE) to reduce the risk of major adverse cardiovascular events (MACE), including heart attack and stroke, in adults with established cardiovascular disease and obesity or overweight.
Worldwide, 1 billion people live with obesity, and in the UAE, 28% of adults are living with obesity, with almost 7.5 million people projected to be living with obesity or overweight by 2035.
Novo Nordisk has previously announced that we will launch Wegovy® pill in select markets in the second half of 2026.
5 Likes
Månedschartet i Novo er ganske compelling. Se momentumindikatorene der, sammen med en mulig vellykket backtest av 50 dagers snitt
1 Like
Det som er negativt er at den lange tunge trenden er intakt